MARKET

BIIB

BIIB

Biogen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

270.01
-0.70
-0.26%
After Hours: 266.00 -4.01 -1.49% 19:45 03/08 EST
OPEN
270.70
PREV CLOSE
270.71
HIGH
278.87
LOW
267.49
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
363.92
52 WEEK LOW
223.25
MARKET CAP
41.13B
P/E (TTM)
11.04
1D
5D
1M
3M
1Y
5Y
Amniotic Membranes Market Statistics and Research Analysis Detailed in Latest Research Report 2021-2028
Mar 08, 2021 (Heraldkeepers) -- The Amniotic Membranes Market is expected to exceed more than US$ 1.63 Billion by 2024 at a CAGR of 9.7% in the given...
Heraldkeepers · 10h ago
Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook
Rating Action: Moody's assigns Ba3 to Alkermes' term loan; stable outlookGlobal Credit Research - 08 Mar 2021New York, March 08, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a su...
Moody's · 11h ago
5 Undervalued Stocks Below the Peter Lynch Value
GuruFocus News · 11h ago
Global Protein Drugs Market Size 2021, Estimate CAGR Value, Growth Rate, Product Demand, Industry Share, Technology, Challenges and Restraints to 2026
Mar 08, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry”. Global “Protein Drugs Market” report gives...
The Express Wire · 19h ago
Here's What Biogen Inc.'s (NASDAQ:BIIB) Shareholder Ownership Structure Looks Like
Simply Wall St. · 1d ago
Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?
Zacks.com · 2d ago
Sometimes Stocks Move Fast, and Biogen Inc. Common Stock $BIIB is no Exception
Mar 05, 2021 (Stock Traders Daily via COMTEX) -- Whether a stock moves fast or slow, one thing is always true. The forces of supply and demand determine the...
Stock Traders Daily · 2d ago
Biogen Inc. stock outperforms competitors on strong trading day
Shares of Biogen Inc. rallied 2.71% to $270.71 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIIB. Analyze the recent business situations of Biogen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 33 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIIB stock price target is 289.76 with a high estimate of 458.00 and a low estimate of 166.00.
EPS
Institutional Holdings
Institutions: 1.65K
Institutional Holdings: 138.54M
% Owned: 90.95%
Shares Outstanding: 152.34M
TypeInstitutionsShares
Increased
280
8.14M
New
287
335.69K
Decreased
426
11.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Stelios Papadopoulos
Chief Executive Officer/Director
Michel Vounatsos
Chief Financial Officer/Executive Vice President
Michael McDonnell
Chief Human Resource Officer/Executive Vice President
Ginger Gregory
Executive Vice President/Secretary
Susan Alexander
Executive Vice President
.. ..
Executive Vice President
Alphonse Galdes
Executive Vice President
Chirfi Guindo
Executive Vice President
Daniel Karp
Executive Vice President
Alfred Sandrock
Senior Vice President/Chief Information Officer
Mark Hernon
Chief Accounting Officer/Vice President
Robin Kramer
Independent Director
Alexander Denner
Independent Director
Caroline Dorsa
Independent Director
William Hawkins
Independent Director
Nancy Leaming
Independent Director
Jesus Mantas
Independent Director
Richard Mulligan
Independent Director
Robert Pangia
Independent Director
Brian Posner
Independent Director
Eric Rowinsky
Independent Director
Stephen Sherwin
No Data
  • All
  • Financials
  • Insiders
More
About BIIB
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.